Everest Medicines Expands Kidney Disease Portfolio with Hainan Herui Collaboration
Event summary
- Everest Medicines partners with Hainan Herui to commercialize budesonide enteric capsules in mainland China, approved by NMPA in December 2025.
- Everest will handle commercialization and provide technical guidance for manufacturing and supply processes.
- Collaboration aims to expand patient access to treatments for IgA nephropathy alongside Everest's NEFECON®.
- NEFECON®, approved in November 2023, is included in China’s National Reimbursement Drug List since November 2024.
The big picture
This collaboration strengthens Everest Medicines' position in the kidney disease treatment sector, particularly in IgA nephropathy. By leveraging its commercialization expertise, Everest aims to expand access to critical therapies in a high-growth market. The deal also underscores the strategic importance of partnerships in scaling innovative treatments across China's regulated pharmaceutical landscape.
What we're watching
- Market Penetration
- How Everest’s commercialization strategy will impact the adoption of budesonide enteric capsules in China.
- Regulatory Compliance
- Whether Everest can maintain rigorous quality audits over Hainan Herui's manufacturing processes.
- Pipeline Synergy
- The pace at which this collaboration will enhance the combined franchise of NEFECON® and budesonide enteric capsules.
Related topics